TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25891091

Group type: EXPERIMENTAL
Intervention: Triple anti-platelet therapy (TAT; aspirin, clopidogrel, and sarpogrelate)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Conventional dual antiplatelet therapy (DAT; aspirin and clopidogrel)
Number of subjects: 220
Study: 23663651

Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral therapy (CBT) - 15 sessions directed at symptom reduction of SUD and ADHD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual - 10 CBT sessions directed at symptom reduction of SUD only
Number of subjects: 0
Study: 21875859

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1944
Study: 20303665

Group type: COMPARATOR
Intervention: Pregabalin (12-week treatment)
Number of subjects: 401
Study: 17593025

Group type: EXPERIMENTAL
Intervention: Low-dose gemtuzumab ozogamicin (GO) added to FLAI chemotherapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-dose gemtuzumab ozogamicin (GO)
Number of subjects: 46

Group type: COMPARATOR
Intervention: FLAI chemotherapy without GO (historical cohort)
Number of subjects: 46
Study: 15888715

Group type: EXPERIMENTAL
Intervention: Screw fixation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cast treatment
Number of subjects: 37
Study: 12468610

Group type: EXPERIMENTAL
Intervention: Vitamin A supplements
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 9812128

Group type: EXPERIMENTAL
Intervention: Right prefrontal transcranial magnetic stimulation at 20 Hz (2-second duration per train, 20 trains/day for 10 treatment days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Left prefrontal transcranial magnetic stimulation at 20 Hz (2-second duration per train, 20 trains/day for 10 treatment days)
Number of subjects: 16
Study: 7639163

Group type: EXPERIMENTAL
Intervention: 120 mg verapamil
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: 180 mg verapamil
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: 360 mg verapamil
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: 540 mg verapamil
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 2495215

Group type: EXPERIMENTAL
Intervention: Deponit 5
Number of subjects: 47

Group type: COMPARATOR
Intervention: Transiderm-Nitro 5
Number of subjects: 47
Study: 326325

Group type: EXPERIMENTAL
Intervention: Procyclidine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29926254

Group type: EXPERIMENTAL
Intervention: Arbitrary face-bow transfer
Number of subjects: 38

Group type: COMPARATOR
Intervention: Average values transfer
Number of subjects: 38
Study: 28735965

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 1790GAHB vaccine at doses ≥1.5/25μg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 1790GAHB vaccine at doses up to 5.9/100μg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intradermal and intranasal administration of 1790GAHB vaccine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 26100336

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 30
Study: 23898925

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 21729566

Group type: EXPERIMENTAL
Intervention: G‐CSF during the steady rise of the WBC count (5 µg/kg subcutaneously until final PBSC apheresis)
Number of subjects: 39

Group type: COMPARATOR
Intervention: G‐CSF subcutaneously (filgrastim) at the first restoration after the initial nadir of the peripheral WBC count (historical control group)
Number of subjects: 39
Study: 19383225

Group type: EXPERIMENTAL
Intervention: Nasal polyposis tissue samples
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal tissue samples)
Number of subjects: 0
Study: 16723054

Group type: EXPERIMENTAL
Intervention: Prilocaine (300 or 400 mg)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Prilocaine (high-concentration/low-volume)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 162
Study: 15314047

Group type: EXPERIMENTAL
Intervention: Mechanical patient lifts
Number of subjects: 61
Study: 11051596

Group type: EXPERIMENTAL
Intervention: Polaprezinc
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (IFN-alpha only)
Number of subjects: 34
Study: 9376990

Group type: EXPERIMENTAL
Intervention: cA2 (chimeric monoclonal antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7680852

Group type: EXPERIMENTAL
Intervention: Normothermic CPB (nasopharyngeal temperature > 34 degrees C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normothermic bypass and administration of high‐dose aprotinin (2 million IU before CPB, 500,000 IU/h until the end of the operation, and 2 million IU added to the prime)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hypothermic CPB (nasopharyngeal temperature < 28 degrees C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hypothermic CPB and aprotinin
Number of subjects: 60
Study: 3531052

Group type: EXPERIMENTAL
Intervention: Trestatin 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trestatin 3 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trestatin 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29098379

Group type: EXPERIMENTAL
Intervention: High height difference position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (corrected hydrostatic pressure)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adjustment for hydrostatic pressure
Number of subjects: 30
Study: 25886707

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids supplementation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24168957

Group type: COMPARATOR
Intervention: Aggressive medical management (antiplatelet therapy, intensive management of vascular risk factors, lifestyle-modification programme)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Aggressive medical management plus stenting with the Wingspan stent
Number of subjects: 451

Group type: COMPARATOR
Intervention: Aggressive medical management
Number of subjects: 451
Study: 22982768

Group type: EXPERIMENTAL
Intervention: Universal pre-school vision screening (PVS) conducted by nurses/CMAs and physicians
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Testing visual acuity by nurses/CMAs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vision screening by physicians
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Barriers to PVS
Number of subjects: 45
Study: 20521033

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 3,900 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 49
Study: 18695807

Group type: EXPERIMENTAL
Intervention: Sterile gauze dressings
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sterilized transparent film dressings
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Non sterile hypoallergenic adhesive tape
Number of subjects: 150
Study: 15643191

Group type: EXPERIMENTAL
Intervention: Topical 0.2% glyceryl trinitrate (GTN) paste
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 11801420

Group type: EXPERIMENTAL
Intervention: Observation of a motoric act (Obs-grasp)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Observation of a complex motoric act (Obs-seq)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Relax (absence of tasks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Actual motor performance
Number of subjects: 15
Study: 10790903

Group type: EXPERIMENTAL
Intervention: Brief intervention to reduce excessive drinking, smoking, and stress
Number of subjects: 954

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 954
Study: 7779733

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (55 Gy in 32-36 fractions of 1.72-1.53 Gy, twice daily for 3 weeks)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Accelerated radiotherapy
Number of subjects: 116
Study: 2264602

Group type: EXPERIMENTAL
Intervention: Volunteers for treatment study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-volunteers for treatment study
Number of subjects: 0
Study: 6986969

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus CMF chemotherapy
Number of subjects: 89
Study: 31654573

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ARC-520
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2 mg/kg ARC-520
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ARC-520
Number of subjects: 90
Study: 29020806

Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 27564385

Group type: EXPERIMENTAL
Intervention: Anticholinergic medications (AC)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Botox
Number of subjects: 231
Study: 25380901

Group type: EXPERIMENTAL
Intervention: Standard dose tacrolimus (group I)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Reduced dose tacrolimus (group II)
Number of subjects: 29
Study: 22517886

Group type: COMPARATOR
Intervention: Control information about cervical cancer
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Details of the link between HPV and cervical cancer
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Risk factor information
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Details about the link with HPV + risk factor information
Number of subjects: 606
Study: 19594741

Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant hormone therapy (NHT) with goserelin acetate and flutamide before radical prostatectomy (RP)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Radical prostatectomy (RP) only
Number of subjects: 148
Study: 17631708

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus imported LMWH treatment group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus indigenous LMWH treatment group
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 75
Study: 15681099

Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (CHOD) 12.6g/100ml, 800 ml evening before surgery and 400 ml on the day of surgery 2-3 hours before anaesthesia.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo drink (control group), 800 ml evening before surgery and 400 ml on the day of surgery 2-3 hours before anaesthesia.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (CHOD)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo drink (control group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 11947915

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily for 16 weeks
Number of subjects: 136

Group type: COMPARATOR
Intervention: Gemfibrozil 1200 mg daily for 16 weeks
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both pravastatin and gemfibrozil
Number of subjects: 136
Study: 10487682

Group type: EXPERIMENTAL
Intervention: Low dose test (LDT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard dose test (SDT)
Number of subjects: 42
Study: 8768619

Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 24
Study: 1872266

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2466
Study: 6345373

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitrendipine 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitrendipine (both doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30889802

Group type: EXPERIMENTAL
Intervention: Mobile diabetes management system (MDMS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 44
Study: 29338073

Group type: EXPERIMENTAL
Intervention: 6 months of androgen deprivation therapy (ADT)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 206
Study: 26606872

Group type: EXPERIMENTAL
Intervention: Sensory approach combined with traditional swallowing therapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Motor approach combined with traditional swallowing therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Traditional swallowing therapy
Number of subjects: 82
Study: 25979762

Group type: EXPERIMENTAL
Intervention: Quantitative methylation-specific PCR (Q-MSP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MethyLight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisulfite pyrosequencing
Number of subjects: 0
Study: 22595020

Group type: EXPERIMENTAL
Intervention: Ubiquinone (400 mg daily for 12 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 49
Study: 18838493

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 17503044

Group type: EXPERIMENTAL
Intervention: Ischaemia released prior to wound closure (Group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ischaemia released after suturing and bandaging (Group B)
Number of subjects: 43
Study: 15759065

Group type: EXPERIMENTAL
Intervention: Telephone interpersonal counseling (TIP-C)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care attentional control
Number of subjects: 48
Study: 11948052

Group type: EXPERIMENTAL
Intervention: Off-pump coronary revascularization
Number of subjects: 22

Group type: COMPARATOR
Intervention: On-pump coronary revascularization
Number of subjects: 22
Study: 10496112

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (HCD)
Number of subjects: 7
Study: 7793589

Group type: EXPERIMENTAL
Intervention: Dopexamine hydrochloride (4-6 micrograms/kg/min) with colloid
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 12
Study: 1920698

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Strength and flexibility training
Number of subjects: 99

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 99
Study: 6355318

Group type: EXPERIMENTAL
Intervention: Ampicillin treatment
Number of subjects: 575

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 575
Study: 31840813

Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP target below 120 mm Hg)
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Standard treatment (SBP target below 140 mm Hg)
Number of subjects: 1167
Study: 31350650

Group type: EXPERIMENTAL
Intervention: Single-use device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reusable device
Number of subjects: 40
Study: 28490554

Group type: EXPERIMENTAL
Intervention: Web-based clinician-focussed clinical rule and printed leaflet with individualised child health information
Number of subjects: 501

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 501
Study: 25727445

Group type: EXPERIMENTAL
Intervention: Sign-Supported English (SSE)
Number of subjects: 104

Group type: COMPARATOR
Intervention: English-only input (Control)
Number of subjects: 104
Study: 25008145

Group type: EXPERIMENTAL
Intervention: Real tDCS treatment (2 mA, 35 cm2, two times daily stimulation for 13 min with a 20‐min interval for five consecutive days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Real tDCS treatment
Number of subjects: 33
Study: 22835219

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (25 mg three times daily for 3 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study: 19444613

Group type: EXPERIMENTAL
Intervention: Acute intake of 15 g of dietary fiber rich in phenolic antioxidants
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (n = 4)
Number of subjects: 10
Study: 17561952

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at a starting dose of 12.5 mg/day, target dose of 50 mg/day for patients <30 kg and 75 mg/day for patients >30 kg over 4 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) at a starting dose of 10 mg/kg/day, target dose of 20 mg/kg/day over 4 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at minimum target dose
Number of subjects: 88
Study: 17382742

Group type: EXPERIMENTAL
Intervention: 0.5 mg dutasteride daily
Number of subjects: 2802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2802
Study: 14751204

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 527
Study: 10836730

Group type: EXPERIMENTAL
Intervention: Valsartan, 80 mg, o.d. (AT1 antagonist)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Benazepril (placebo)
Number of subjects: 20
Study: 9108809

Group type: EXPERIMENTAL
Intervention: Lithium plus divalproex sodium
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lithium alone (placebo group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 8476409

Group type: EXPERIMENTAL
Intervention: Social Phobia and Anxiety Inventory (SPAI)
Number of subjects: 0
Study: 3957880

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 24
Study: 30626650

Group type: EXPERIMENTAL
Intervention: l-serine (400 mg/kg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28435240

Group type: EXPERIMENTAL
Intervention: Budesonide-containing treatments (budesonide/formoterol or budesonide)
Number of subjects: 10570

Group type: COMPARATOR
Intervention: Non-budesonide-containing treatments (formoterol or placebo)
Number of subjects: 10570

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 10570

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 10570
Study: 24909399

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (B‐TURP) using the TURis system
Number of subjects: 136

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (M‐TURP)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (B‐TURP) using the TURis system in patients with prostate volume >70 mL
Number of subjects: 136

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (M‐TURP) in patients with prostate volume >70 mL
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (B‐TURP) using the TURis system in patients with prostate volume ≤ 70 mL
Number of subjects: 136
Study: 23800443

Group type: EXPERIMENTAL
Intervention: Supportive text messages delivered twice daily for three months (n=24)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fortnightly thank you text message (n=24)
Number of subjects: 54
Study: 20689965

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g/day)
Number of subjects: 39
Study: 22253969

Group type: EXPERIMENTAL
Intervention: High Dairy (HD; three dairy servings, diet totaling 1,400 mg/day)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: High Dairy (HD)
Number of subjects: 106

Group type: COMPARATOR
Intervention: High Calcium (HC; 1,400 mg/day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Low Calcium (LC; 600 mg/day)
Number of subjects: 106
Study: 11434192

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day
Number of subjects: 846

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 846

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Simvastatin (both doses)
Number of subjects: 846

Group type: COMPARATOR
Intervention: Atorvastatin (both doses)
Number of subjects: 846
Study: 10024195

Group type: EXPERIMENTAL
Intervention: Persian Gulf-deployed veterans (n = 291)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Self-reported exposures to pesticides, debris from Scuds, chemical and biological warfare agents, and smoke from tent heaters
Number of subjects: 341

Group type: COMPARATOR
Intervention: Germany veterans (n = 50)
Number of subjects: 341
Study: 8311291

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both ranitidine 50 mg and metoclopramide 10 mg
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 3049846

Group type: EXPERIMENTAL
Intervention: Nifedipine 80 mg/day
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 30347089

Group type: EXPERIMENTAL
Intervention: Aspirin only
Number of subjects: 41537

Group type: COMPARATOR
Intervention: Anticoagulant only
Number of subjects: 41537

Group type: COMPARATOR
Intervention: Both aspirin and anticoagulant
Number of subjects: 41537

Group type: COMPARATOR
Intervention: No pharmacologic prophylaxis
Number of subjects: 41537
Study: 26849409

Group type: EXPERIMENTAL
Intervention: Peer-coach and nurse-partnered interventions
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Substance abuse program contract within a residential drug treatment program
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Spent 90 days or greater in a residential drug treatment program
Number of subjects: 600
Study: 25146492

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (1 g/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (same fruit drink without omega-3)
Number of subjects: 200